September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
REAL LIFE SETTING TREATMENT BY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR WET AGE-RELATED MACULAR DEGENERATION: INACTIVATION OF LESION AND LONG TERM OUTCOMES
Author Affiliations & Notes
  • Mohamed Maher Haouas
    Ophtalmology, Hospital North, Saint-Etienne, France
    DHU SightRestore, Quinze-Vingts National Hospital, Paris, France
  • Gilles Thuret
    Ophtalmology, Hospital North, Saint-Etienne, France
    France University Institute, Paris, France
  • Philippe GAIN
    Ophtalmology, Hospital North, Saint-Etienne, France
  • Michel Paques
    DHU SightRestore, Quinze-Vingts National Hospital, Paris, France
  • Jose Sahel
    DHU SightRestore, Quinze-Vingts National Hospital, Paris, France
  • Jean-Francois GIRMENS
    DHU SightRestore, Quinze-Vingts National Hospital, Paris, France
  • Footnotes
    Commercial Relationships   Mohamed Maher Haouas, None; Gilles Thuret, None; Philippe GAIN, None; Michel Paques, None; Jose Sahel, None; Jean-Francois GIRMENS, BAYER (C), NOVARTIS (C)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3333. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Mohamed Maher Haouas, Gilles Thuret, Philippe GAIN, Michel Paques, Jose Sahel, Jean-Francois GIRMENS; REAL LIFE SETTING TREATMENT BY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR WET AGE-RELATED MACULAR DEGENERATION: INACTIVATION OF LESION AND LONG TERM OUTCOMES. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3333.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the percentage of treatment discontinuation because of inactivation of lesion and the long-term visual outcomes for patients receiving a real life setting treatment by anti-vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (AMD).

Methods : Retrospective chart review of 445 eyes of 400 patients who received a first anti-VEGF injection for wet AMD from January 1, 2006 to December 31, 2009 at the Quinze-Vingts National Hospital (Paris), with at least 5 years of follow-up. Patients clinical characteristics, ETDRS letter score at baseline, every years and at the last follow-up were recorded. The number of injections and the date of the first and last injection were also recorded.

Results : 148 eyes of 122 patients with at least 5 years of follow-up were identified (follow-up of 77,7 month). Seventy percent of those eyes was untreated since 6 months or more at the last follow-up (inactivation of lesion). Mean duration of treatment was 47,4 months, with an average of 12 injections per eye. For the 118 remaining eyes with full visual data, mean change in letter score at 5, 6 and 7 years was respectively + 1,6 letters, -1,6 letters and – 4,7 letters. A vision of 20/40 or better was achieved in 29,4% of treated eyes..

Conclusions : Real life setting treatment of neovascular AMD by anti-VEGF results in a stabilization of vision at 5 and 6 years of treatment. Inactivation of lesion of more than 50% of treated eyes at 5 years challenges the fixed-dosing regimen in benefit of a personalized one. Given the life expectancy of patients at the initiation of treatment, long term visual outcomes of anti-VEGF are satisfactory.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×